A Phase 3 interventional study of Baricitinib and Methotrexate in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 154 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-19.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is one of 3 that started in 2012, is one of 8 in phase 3, and was the 6th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
Galvani Bioelectronics · Sites in United States, Netherlands
Ages 22–75
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 588 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
35 studies in Arthritis, Rheumatoid by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 9th largest by enrollment, is one of 5 that started in 2012, is one of 11 in phase 3, and was the 21st registered.
Eli Lilly and Company’s Arthritis, Rheumatoid studies by the year they started, since 2005.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 35 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether baricitinib therapy alone is noninferior to methotrexate (MTX) therapy alone in the treatment of moderate to severe active rheumatoid arthritis (RA) in those who have had limited or no treatment with MTX and are naive to other conventional or biologic disease-modifying antirheumatic drugs (DMARDs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Baricitinib 4 milligram (mg) administered orally once daily through Week 52. Participants received methotrexate (MTX) orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
Drug: Baricitinib · Drug: Methotrexate · Drug: Folic Acid
Baricitinib 4 mg administered orally once daily through Week 52. Participants received MTX placebo orally once weekly through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
Drug: Baricitinib · Drug: MTX Placebo · Drug: Folic Acid
MTX administered orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Participants also received baricitinib placebo orally once daily. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
Drug: Methotrexate · Drug: Baricitinib Placebo · Drug: Folic Acid
Administered orally
Also known as: LY3009104
Administered orally
Baricitinib placebo administered orally once daily.
MTX placebo administered orally once weekly.
Administered orally every day
Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.
Time frame: Week 24
Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.
Time frame: Week 52
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
HAQ-DI assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area are averaged to calculate the HAQ-DI score, which ranges from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicates an improvement in the participant's condition.
Time frame: Baseline, Week 24
Change From Baseline in the Disease Activity Score Based on a 28-Joint Count and High-sensitivity C-reactive Protein (DAS28-hsCRP)
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using the following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Baseline, Week 24
Change From Baseline in the Modified Total Sharp Score (mTSS)
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS (van der Heijde 2000). This methodology quantified the extent of bone erosions and joint space narrowing for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448.
Time frame: Baseline, Week 24
Percentage of Participants Who Achieved a Simplified Disease Activity Index (SDAI) Score ≤3.3
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.
Time frame: Week 24
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
ACR50 Responder Index is composite of clinical, laboratory, and functional measures in RA. "ACR50 Responder" is a participant who has at least 50% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.
Time frame: Week 12, Week 24, Week 52
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 Responder Index is composite of clinical, laboratory, and functional measures in RA. "ACR70 Responder" is a participant who has at least 70% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinued study or drug or were rescued before analysis timepoint were deemed non-responders.
Time frame: Week 12, Week 24, Week 52
Change From Baseline in Clinical Disease Activity Index (CDAI) Score
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Time frame: Baseline, Week 24; Baseline, Week 52
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)
DAS28 consisted of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), erythrocyte sedimentation rate (ESR) (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using the following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Baseline, Week 24; Baseline, Week 52
Percentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Remission
The ACR/EULAR definitions of RA remission include a "Boolean-based definition". The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 ≤1, SJC28 ≤1, acute phase response using C-reactive protein (milligrams per deciliter) ≤1, Patient's Global Assessment of Disease Activity using VAS (cm) ≤1.
Time frame: Week 12, Week 24, Week 52
Change From Baseline in Joint Space Narrowing and Bone Erosion Scores
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing. The bone erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints, with 0 indicating no erosion and the highest score (5 for the hand and 10 for the foot) indicating extensive loss of bone from more than one half of the articulating bone. Erosion scores ranged from 0 (no erosion) to 280 (high erosion).
Time frame: Baseline, Week 24; Baseline, Week 52
Change From Baseline in Duration of Morning Joint Stiffness
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
Time frame: Baseline, Week 52
Change From Baseline in Worst Tiredness Numeric Rating Scale (NRS)
Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine".
Time frame: Baseline, Week 24; Baseline Week 52
Change From Baseline in Worst Joint Pain Numeric Rating Scale (NRS)
Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine".
Time frame: Baseline, Week 24; Baseline Week 52
Change From Baseline in Mental Component Score (MCS) and Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.
Time frame: Baseline, Week 24; Baseline Week 52
Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. One component consists of a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
Time frame: Baseline, Week 24; Baseline Week 52
Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
A second component of the EQ-5D-5L is a self-perceived health score which is assessed using a VAS that ranges from 0 to 100 millimeter (mm), where 0 indicates the worst health you can imagine and 100 indicates the best health you can imagine.
Time frame: Baseline, Week 24; Baseline Week 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scores
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.
Time frame: Baseline, Week 24; Baseline Week 52
Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores
The Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. It contains 6 items covering overall work productivity (health), overall work productivity (symptom), impairment of regular activities (health), and impairment of regular activities (symptom). Scores are calculated as impairment percentages. The WPAI-RA yields four types of scores: Absenteeism (work time missed), Presenteeism (impairment at work), Work productivity loss (overall work impairment), and Activity impairment.
Time frame: Baseline, Week 24; Baseline Week 52
Population Pharmacokinetics (PK): Peak Concentration at Steady State (Cmax,ss) of Baricitinib
Time frame: Week 0: 15 and 60 minutes postdose; Week 4: 2 to 4 hours post-dose; Week 8: 4 to 6 hours post-dose; Week 12; Week 24; Week 32; Pre-dose
Population PK: Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib
Time frame: Week 0: 15 and 60 minutes postdose; Week 4: 2 to 4 hours post-dose; Week 8: 4 to 6 hours post-dose; Week 12; Week 24; Week 32; Pre-dose
| Milestone | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Started | 213 | 160 | 215 |
| Received at least one dose of study drug | 210 | 159 | 215 |
| Rescued | 26 | 7 | 6 |
| Completed | 161 | 136 | 173 |
| Not completed | 52 | 24 | 42 |
| Withdrew: Withdrawal by subject | 18 | 7 | 13 |
| Withdrew: Lack of efficacy | 13 | 2 | 2 |
| Withdrew: Adverse event | 8 | 10 | 24 |
| Withdrew: Physician decision | 4 | 3 | 2 |
| Withdrew: Death | 3 | 0 | 0 |
| Withdrew: Entry criteria not met | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 |
| Withdrew: Randomized, not treated | 3 | 1 | 0 |
| Milestone | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Started | 25 | 15 | 28 |
| Completed | 0 | 0 | 0 |
| Not completed | 25 | 15 | 28 |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.
| Percent of participants | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) | 61.9 | 76.7 | 78.1 |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.
| Percent of participants | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) | 55.7 | 73.0 | 72.6 |
HAQ-DI assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area are averaged to calculate the HAQ-DI score, which ranges from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicates an improvement in the participant's condition.
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score | -0.73 ± 0.71 | -1.01 ± 0.74 | -0.92 ± 0.74 |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using the following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Change From Baseline in the Disease Activity Score Based on a 28-Joint Count and High-sensitivity C-reactive Protein (DAS28-hsCRP) | -2.01 ± 1.51 | -2.74 ± 1.39 | -2.82 ± 1.58 |
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS (van der Heijde 2000). This methodology quantified the extent of bone erosions and joint space narrowing for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448.
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Change From Baseline in the Modified Total Sharp Score (mTSS) | 0.64 ± 1.81 | 0.43 ± 1.18 | 0.32 ± 1.14 |
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.
| percentage of participants | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Percentage of Participants Who Achieved a Simplified Disease Activity Index (SDAI) Score ≤3.3 | 10.5 | 22.0 | 22.8 |
ACR50 Responder Index is composite of clinical, laboratory, and functional measures in RA. "ACR50 Responder" is a participant who has at least 50% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.
| Percent of participants | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Week 12 | 32.9 | 54.7 | 60.0 |
| Week 24 | 43.3 | 59.7 | 63.3 |
| Week 52 | 37.6 | 57.2 | 61.9 |
ACR70 Responder Index is composite of clinical, laboratory, and functional measures in RA. "ACR70 Responder" is a participant who has at least 70% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinued study or drug or were rescued before analysis timepoint were deemed non-responders.
| Percent of participants | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Week 12 | 15.7 | 30.8 | 33.5 |
| Week 24 | 21.4 | 42.1 | 39.5 |
| Week 52 | 25.2 | 42.1 | 46.0 |
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Week 24 | -22.12 ± 16.12 | -28.20 ± 13.96 | -29.86 ± 14.05 |
| Week 52 | -21.95 ± 18.07 | -28.94 ± 14.58 | -30.72 ± 14.87 |
DAS28 consisted of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), erythrocyte sedimentation rate (ESR) (millimeters per hour), and Patient's Global Assessment of Disease Activity. DAS28 was calculated using the following formula: DAS28-ESR=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.70\*natural log(ESR)+0.014\*Patient's Global VAS. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Week 24 | -2.20 ± 1.53 | -2.76 ± 1.45 | -3.06 ± 1.46 |
| Week 52 | -2.32 ± 1.77 | -2.84 ± 1.57 | -3.22 ± 1.48 |
The ACR/EULAR definitions of RA remission include a "Boolean-based definition". The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 ≤1, SJC28 ≤1, acute phase response using C-reactive protein (milligrams per deciliter) ≤1, Patient's Global Assessment of Disease Activity using VAS (cm) ≤1.
| percentage of participants | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Week 12 | 5.7 | 13.8 | 14.4 |
| Week 24 | 8.6 | 18.9 | 16.3 |
| Week 52 | 11.4 | 17.0 | 20.9 |
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing. The bone erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints, with 0 indicating no erosion and the highest score (5 for the hand and 10 for the foot) indicating extensive loss of bone from more than one half of the articulating bone. Erosion scores ranged from 0 (no erosion) to 280 (high erosion).
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| JSN Week 24 | 0.15 ± 0.94 | 0.08 ± 0.44 | 0.05 ± 0.44 |
| JSN Week 52 | 0.23 ± 1.00 | 0.26 ± 1.14 | 0.08 ± 0.88 |
| Bone Erosion Week 24 | 0.49 ± 1.14 | 0.35 ± 0.92 | 0.27 ± 0.95 |
| Bone Erosion Week 52 | 0.80 ± 1.80 | 0.55 ± 1.48 | 0.33 ± 1.21 |
Participants reported the duration of their morning joint stiffness (MJS) in hours and minutes. The participants were asked about their duration of morning joint stiffness on the day prior to the study visit to capture actual symptoms, since the participant may have had an atypical morning routine on the day of the study visit. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
| Minutes | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Change From Baseline in Duration of Morning Joint Stiffness | -40.0 (-55.0 to -30.0) | -55.0 (-60.0 to -40.0) | -60.0 (-80.0 to -50.0) |
Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine".
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Week 24 | -2.2 ± 2.7 | -3.0 ± 3.1 | -3.0 ± 2.8 |
| Week 52 | -2.3 ± 2.8 | -2.9 ± 3.1 | -3.0 ± 2.9 |
Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine".
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Week 24 | -2.8 ± 2.5 | -3.9 ± 2.7 | -3.9 ± 2.6 |
| Week 52 | -3.0 ± 2.8 | -3.9 ± 2.9 | -4.1 ± 2.7 |
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| MCS Week 24 | 3.4 ± 10.8 | 5.9 ± 11.7 | 4.6 ± 11.6 |
| MCS Week 52 | 2.4 ± 10.9 | 5.8 ± 11.9 | 5.0 ± 11.5 |
| PCS Week 24 | 9.4 ± 9.2 | 12.5 ± 9.1 | 13.2 ± 9.6 |
| PCS Week 52 | 9.4 ± 10.1 | 11.6 ± 9.6 | 13.3 ± 9.8 |
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. One component consists of a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Index Score (US Algorithm) Week 24 | 0.142 ± 0.189 | 0.197 ± 0.164 | 0.194 ± 0.180 |
| Index Score (US Algorithm) Week 52 | 0.138 ± 0.203 | 0.186 ± 0.177 | 0.185 ± 0.186 |
| Index Score (UK Algorithm) Week 24 | 0.205 ± 0.274 | 0.285 ± 0.241 | 0.282 ± 0.255 |
| Index Score (UK Algorithm) Week 52 | 0.197 ± 0.294 | 0.271 ± 0.258 | 0.268 ± 0.266 |
A second component of the EQ-5D-5L is a self-perceived health score which is assessed using a VAS that ranges from 0 to 100 millimeter (mm), where 0 indicates the worst health you can imagine and 100 indicates the best health you can imagine.
| millimeter | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Self-Perceived Health Week 24 | 14.5 ± 28.3 | 24.1 ± 26.0 | 21.4 ± 31.4 |
| Self-Perceived Health Week 52 | 13.6 ± 30.1 | 24.5 ± 28.7 | 24.5 ± 30.6 |
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.
| units on a scale | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Week 24 | 9.3 ± 11.2 | 13.0 ± 10.8 | 12.3 ± 11.5 |
| Week 52 | 9.1 ± 10.9 | 11.3 ± 10.8 | 12.6 ± 11.8 |
The Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. It contains 6 items covering overall work productivity (health), overall work productivity (symptom), impairment of regular activities (health), and impairment of regular activities (symptom). Scores are calculated as impairment percentages. The WPAI-RA yields four types of scores: Absenteeism (work time missed), Presenteeism (impairment at work), Work productivity loss (overall work impairment), and Activity impairment.
| Percentage of Impairment | Methotrexate | Baricitinib | Baricitinib + MTX |
|---|---|---|---|
| Absenteeism Week 24 (n=76, 56, 90) | -3.6 ± 35.5 | -8.7 ± 30.4 | -7.6 ± 26.5 |
| Absenteeism Week 52 (n=52, 51, 71) | -3.0 ± 29.2 | -8.4 ± 29.7 | -7.3 ± 21.8 |
| Presenteeism Week 24(n=70, 51, 86) | -19 ± 25 | -26 ± 27 | -32 ± 26 |
| Presenteeism Week 52 (n=51, 47, 75) | -26 ± 26 | -27 ± 24 | -33 ± 25 |
| Work Productivity Loss Week 24 (n=70, 71, 86) | -17.8 ± 30.2 | -25.6 ± 29.1 | -30.9 ± 29.6 |
| Work Productivity Loss Week 52 (n=51, 47, 75) | -24.1 ± 30.5 | -27.6 ± 27.3 | -33.8 ± 27.5 |
| Activity Impairment Week 24 (n=184, 145, 192) | -25 ± 26 | -36 ± 28 | -31 ± 28 |
| Activity Impairment Week 52 (n=141, 131, 172) | -28 ± 27 | -34 ± 27 | -37 ± 27 |
| nanomole/Liter (nmol/L) | Baricitinib |
|---|---|
| Population Pharmacokinetics (PK): Peak Concentration at Steady State (Cmax,ss) of Baricitinib | 135 ± 23.1 |
| nanomole/Liter (nmol/L) | Baricitinib |
|---|---|
| Population PK: Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib | 1280 ± 47.2 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Methotrexate | — | 20/210 (9.5%) | 115/210 (54.8%) |
| Baricitinib | — | 12/159 (7.5%) | 81/159 (50.9%) |
| Baricitinib + MTX | — | 17/215 (7.9%) | 129/215 (60%) |
| Rescue Period | — | 1/39 (2.6%) | 21/39 (53.8%) |
| Methotrexate - Follow-up | — | 0/25 (0%) | 2/25 (8%) |
| Baricitinib - Follow-up | — | 0/15 (0%) | 2/15 (13.3%) |
| Baricitinib + MTX - Follow-up | — | 0/28 (0%) | 0/28 (0%) |
| Event | Methotrexate | Baricitinib | Baricitinib + MTX | Rescue Period | Methotrexate - Follow-up | Baricitinib - Follow-up | Baricitinib + MTX - Follow-up |
|---|---|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/210 | 0/159 | 0/215 | 1/39 | 0/25 | 0/15 | 0/28 |
| Herpes zosterInfections and infestations | 2/210 | 1/159 | 0/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| FallInjury, poisoning and procedural complications | 2/210 | 0/159 | 0/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| Spinal compression fractureInjury, poisoning and procedural complications | 2/210 | 0/159 | 0/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| Coronary artery diseaseCardiac disorders | 0/210 | 1/159 | 0/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| Myocardial infarctionCardiac disorders | 0/210 | 1/159 | 0/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| Duodenal ulcerGastrointestinal disorders | 0/210 | 1/159 | 0/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| FatigueGeneral disorders | 0/210 | 1/159 | 0/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| Oedema peripheralGeneral disorders | 0/210 | 1/159 | 0/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| CholecystitisHepatobiliary disorders | 0/210 | 1/159 | 0/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| Event | Methotrexate | Baricitinib | Baricitinib + MTX | Rescue Period | Methotrexate - Follow-up | Baricitinib - Follow-up | Baricitinib + MTX - Follow-up |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 17/210 | 16/159 | 21/215 | 1/39 | 0/25 | 0/15 | 0/28 |
| NauseaGastrointestinal disorders | 13/210 | 7/159 | 20/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| Upper respiratory tract infectionInfections and infestations | 15/210 | 12/159 | 16/215 | 1/39 | 0/25 | 0/15 | 0/28 |
| ConstipationGastrointestinal disorders | 3/210 | 2/159 | 7/215 | 0/39 | 0/25 | 1/15 | 0/28 |
| Eczema asteatoticSkin and subcutaneous tissue disorders | 0/210 | 0/159 | 0/215 | 0/39 | 0/25 | 1/15 | 0/28 |
| MiliariaSkin and subcutaneous tissue disorders | 0/210 | 0/159 | 0/215 | 0/39 | 0/25 | 1/15 | 0/28 |
| Seborrhoeic dermatitisSkin and subcutaneous tissue disorders | 0/210 | 0/159 | 0/215 | 0/39 | 0/25 | 1/15 | 0/28 |
| Urinary tract infectionInfections and infestations | 7/210 | 6/159 | 14/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| GastroenteritisInfections and infestations | 4/210 | 10/159 | 6/215 | 0/39 | 0/25 | 0/15 | 0/28 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/210 | 5/159 | 6/215 | 1/39 | 0/25 | 0/15 | 0/28 |
Modified Intent-to-Treat (mITT) population includes all randomized participants who received at least 1 dose of the study drug.
| Age, Continuous(years) | Methotrexate | Baricitinib | Baricitinib + MTX | Total |
|---|---|---|---|---|
| Mean | 50.5 ± 13.4 | 50.9 ± 13.0 | 48.5 ± 13.5 | 49.9 ± 13.4 |
| Sex: Female, Male(Participants) | Methotrexate | Baricitinib | Baricitinib + MTX | Total |
|---|---|---|---|---|
| Female | 148 | 121 | 156 | 425 |
| Male | 62 | 38 | 59 | 159 |
| Race (NIH/OMB)(Participants) | Methotrexate | Baricitinib | Baricitinib + MTX | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 11 | 10 | 20 | 41 |
| Asian | 60 | 44 | 61 | 165 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 5 | 10 | 25 |
| White | 128 | 98 | 123 | 349 |
| More than one race | 1 | 2 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Methotrexate | Baricitinib | Baricitinib + MTX | Total |
|---|---|---|---|---|
| Argentina | 41 | 29 | 33 | 103 |
| Austria | 1 | 1 | 1 | 3 |
| Belgium | 6 | 10 | 11 | 27 |
| Brazil | 8 | 3 | 9 | 20 |
| Canada | 5 | 5 | 7 | 17 |
| Germany | 5 | 5 | 4 | 14 |
| Greece | 0 | 0 | 1 | 1 |
| India | 18 | 12 | 17 | 47 |
| Italy | 8 | 2 | 4 | 14 |
| Japan | 36 | 29 | 39 | 104 |
| Mexico | 12 | 14 | 20 | 46 |
| Portugal | 1 | 0 | 2 | 3 |
| Russian Federation | 11 | 13 | 12 | 36 |
| South Africa | 7 | 4 | 9 | 20 |
| Korea, Republic of | 4 | 1 | 2 | 7 |
| Sweden | 3 | 0 | 1 | 4 |
| United Kingdom | 7 | 3 | 4 | 14 |
| United States | 37 | 28 | 39 | 104 |
| Duration of Rheumatoid Arthritis(years) | Methotrexate | Baricitinib | Baricitinib + MTX | Total |
|---|---|---|---|---|
| Median | 0.2 (0.1 to 0.6) | 0.2 (0.1 to 1.1) | 0.2 (0.1 to 1.0) | 0.2 (0.1 to 0.8) |
| Tender Joint Count of 68 evaluable joints(number of joints) | Methotrexate | Baricitinib | Baricitinib + MTX | Total |
|---|---|---|---|---|
| Mean | 26.5 ± 14.8 | 26.4 ± 14.1 | 27.7 ± 14.5 | 26.9 ± 14.5 |
| Swollen Joint Count of 66 evaluable joints(number of joints) | Methotrexate | Baricitinib | Baricitinib + MTX | Total |
|---|---|---|---|---|
| Mean | 16.4 ± 10.6 | 16.1 ± 9.2 | 16.3 ± 9.5 | 16.3 ± 9.8 |
| High sensitivity C-reactive protein(milligrams per liter (mg/L)) | Methotrexate | Baricitinib | Baricitinib + MTX | Total |
|---|---|---|---|---|
| Mean | 22.34 ± 21.78 | 23.75 ± 26.24 | 24.27 ± 29.42 | 23.44 ± 25.98 |
Showing the first 100 of 154 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Nov 2012, a primary completion of Feb 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 2 years 6 months after primary completion. A results delay was requested in May 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Baricitinib · Methotrexate